Advertisement Β· 728 Γ— 90
#
Hashtag
#OncoNeph
Advertisement Β· 728 Γ— 90

And the full rounds are available here
www.youtube.com/watch?v=_iXs...

Excellent, thorough overview of all sorts of strange and wonderful nephrotoxicity one can expect to see

@aisha-shaikh.bsky.social #NephGR #OncoNeph

9 2 0 0
Figure 1 Timing of recurrence of various plasma cell dyscrasia in kidney transplant allograft. LCCN: light chain cast nephropathy, LCPT: light chain proximal tubulopathy, C3G: C3 glomerulopathy, PGNMID: proliferative glomerulitis with immunoglobulin deposits

Figure 1 Timing of recurrence of various plasma cell dyscrasia in kidney transplant allograft. LCCN: light chain cast nephropathy, LCPT: light chain proximal tubulopathy, C3G: C3 glomerulopathy, PGNMID: proliferative glomerulitis with immunoglobulin deposits

Figure 2 Decision Tree for MM Patients with ESKD Based on Risk Category and Response to Therapy

Figure 2 Decision Tree for MM Patients with ESKD Based on Risk Category and Response to Therapy

Plasma cell dyscrasia and transplant - excellent review in @kidneyint.bsky.social

www.kidney-international.org/article/S008...

From @nymurakami.bsky.social et al

#NephSky #OncoNeph

12 3 0 0

Check out this from Dr Meghan Sise #NephGR for us on the topic

youtu.be/qFYVhjpnYIU?...

#OncoNeph #NephSky

4 1 1 0
Post image

Dr Meghan Sise presenting on serum cr/cystatin outcomes in patients treated with cisplatin or carboplatin

#Onconeph #ERA25

2 0 0 0

Continuing our discussion on oncological emergencies from last week, let's tackle malignant hypercalcemia, which occurs in 20-30% of malignancies with a grim prognosis.

A must-know🧡 for medicine trainees!

#PhysiologyFriday #MedSky #NephSky #OncSky #Onconeph #MedStudentSky

0 1 1 0
Take home messages for ICI nephrotoxicity

Take home messages for ICI nephrotoxicity

Take home messages for ICI nephrotoxicity

Take home messages for ICI nephrotoxicity

Dr Rosner had cool β€˜key messages’ interspersed throughout his talk

#ISNWCN #Nephsky #Onconeph

0 1 0 0
Figure 4 Approach to immune checkpoint inhibitor (ICPI) nephrotoxicity.βˆ—Treat the underlying disease. AKI, acute kidney injury; ATI, acute tubular injury; ATIN, acute tubulointerstitial nephritis; GN, glomerulonephritis; IrAE, immune-related adverse event; RBC, red blood cell; RTEC, renal tubular epithelial cell; WBC, white blood cell.

Figure 4 Approach to immune checkpoint inhibitor (ICPI) nephrotoxicity.βˆ—Treat the underlying disease. AKI, acute kidney injury; ATI, acute tubular injury; ATIN, acute tubulointerstitial nephritis; GN, glomerulonephritis; IrAE, immune-related adverse event; RBC, red blood cell; RTEC, renal tubular epithelial cell; WBC, white blood cell.

This is the algorithm he prefers from a 2020 for biopsy and management www.kidney-international.org/article/S008...
2020 @kidneyint.bsky.social - looks #OpenAccess

#ISNWCN #NephSky #Onconeph

Watch this space for biomarkers I say 😎

5 2 1 0
Electrolyte issues with CAR-T

Electrolyte issues with CAR-T

Conclusions 
AKI mostly CRS
Don’t forget HypoPO4

Conclusions AKI mostly CRS Don’t forget HypoPO4

And don’t forget electrolyte issues from CAR-T
HypoNa likely from Cancer
Hypo from po intake
HypoPO4 truly from CAR-T

#ISNWCN #NephSky #Onconeph

4 1 0 0
Management of AKI in CAR-T  induced CRS

Management of AKI in CAR-T induced CRS

Yale pharmacy guidance for management

Yale pharmacy guidance for management

Management is mostly around supportive care

Steroids
IL-6 inhibition in more severe cases

#onconeph #NephSky #ISNWCN

5 1 1 0
Post image

Join for the Onconeph education series
#onconeph

7 2 0 0